Skip to content

Clinical Trial for the Behavioral and Neuroimaging Study of Deng Zhan Sheng Mai Capsules Intervenes in Vascular Cognitive Impairment

Clinical Trial for the Behavioral and Neuroimaging Study of Deng Zhan Sheng Mai Capsules Intervenes in Vascular Cognitive Impairment

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16009289
Enrollment
Unknown
Registered
2016-09-27
Start date
2016-09-28
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vascular cognitive impairment

Interventions

Group A:Dengzhan Shengmai Jiaonang
Group B:placebo

Sponsors

Centre for Beijing Aging Brain Rejuvenation initiative.Beijing Normal University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: All the following 7 items are required to be met: 1. Accord with likely VaD diagnosis established by DSM-V or NINDS-AIREN or vascular cognitive impairment; 2. Hachinski ischemia scale score more than 4; 3. There is clear history of ischemic stroke or multipleh lacunar infarction,leukoencephalopathy as well as multipleh brain microbleeds confirmed by MRI; 4. MMSE score more than 11 less than 26, in accordance with mild or moderate diagnosis of cognition impairment; 5. Aged between 45 to 80; 6. The patients are voluntary to participate in clinical trial and signed the informed consent; 7. There is certain cultural degree, Cooperate with project research and scale test.

Exclusion criteria

Exclusion criteria: Subjects would be excluded when complied any of following items: 1. Degenerative dementia sunch as AD,FTD,DLB etc.; 2. Hachinski ischemia scale score less than 4; 3. Hamilton's depression scale score more than 17depressionpsychosismental disorders; 4. Having disease disturbed cognitive function evaluation, including addicted to drinking, drug and psychotropic medications during the past five years; 5. Severe neurological function deficit that can not finish the related examine,such as convenient hand hemiplegia, aphasia, visual and hearing difficulty; 6. ever used similar drugs in the past 30 days, such as antagonism drugs,psychiatric drugs, oral anticoagulants,blood-activating and stasis-eliminating compound,and short-acting diazepam; 7. Patients can not be performed with MRI which has accepted pacemaker surgery, coronary intervention surgery or coronary artery bypass surgery; 8. Allergy to drug used in this trial; 9. Participate in other clinic drug trials.

Design outcomes

Primary

MeasureTime frame
Alzheimer's disease assessment scale, ADAS-cog;Mini-Mental Status Examination;Trail Making Test;Stroop Color-word Test;Clock Drawing Test;Auditory Verbal Learning Test;Rey-Osterrich Complex Figure Test;Symbol Digit Modalities Test;Verbal Fluency Test;Boston Naming Test;Montreal Cognitive Assessment scale, MoCA;

Secondary

MeasureTime frame
NIH Stroke Scale;activity of daily living;

Countries

China

Contacts

Public ContactZhanJun ZHANG

Centre for Beijing Aging Brain Rejuvenation initiative.Beijing Normal University

zhang_rzs@bnu.edu.cn+86 010 58802005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026